NeOnc Technologies hosts call on Phase 2a topline data for intranasal NEO100 in recurrent IDH1-mutant glioma - NTHI News | RalliesNeOnc Technologies hosts call on Phase 2a topline data for intranasal NEO100 in recurrent IDH1-mutant glioma
N
NTHI• Upcoming investor call on Phase 2a topline data
- NeOnc Technologies scheduled an Aug. 12, 2026 investor call to present topline Phase 2a results for intranasal NEO100.
- Results have not yet been presented; management plans to disclose efficacy and safety observations from the NEO100-01 study.
- The trial evaluates NEO100 in recurrent or progressive Grade III-IV IDH1-mutant high-grade glioma, a setting with limited treatment options.
- Planned regulatory next steps will be discussed, signaling potential progression toward later-stage development if findings support it.
•
